Personalized medicine was presented to Senate President Maria Elisabetta Alberti Casellati

IRS personalized medicine presented to Senate President Maria Elisabetta Alberti Casellati

IRS presented Tichep project to Senate President Maria Elisabetta Alberti Casellati at the Polo Tecnologico Alto Adriatico.
The TICheP project developed an innovative technological framework for the development of personalized chemotherapy to enable treatment with reduced toxicity.
The study used ovarian carcinoma as a model, but has the potential for extension to other tumor types.

TGR FVG showing our Tichep prototype at the end of the video

Some links
https://www.irsweb.it/notizie/la-medicina-personalizzata-irs-presidente-del-senato-casellati
https://twitter.com/IRSweb
https://www.facebook.com/IRS.padova
https://www.linkedin.com/feed/update/urn:li:activity:6933370632243957760

Event: innovative technological framework for the development of personalized chemotherapy

EVENT WILL BE HELD APRIL 28, 2022, H 10:00-11:30 a.m. AT THE HIGH ADRIATIC TECHNOLOGY POLE-BLUE ROOM AND ON THE ZOOM PLATFORM

Despite advances in cancer treatment, chemotherapy drug resistance and interindividual differences in sensitivity to drug treatment remain a substantial obstacle to cure for many patients.
The TICheP project developed an innovative technological framework for the development of personalized chemotherapy to enable treatment with reduced toxicity.
The study used ovarian carcinoma as a model, but has the potential for extension to other tumor types.

AGENDA

       10:00 Institutional greetings

Franco Scolari – General director of Polo Tecnologico Alto Adriatico

       10:15 Role of the Regional Life Sciences Cluster in supporting innovative projects

Angela Dosso – Cluster Manager Cluster Life Sciences FVG

       10:30 TiChep: an application example of a personalized chemotherapy platform

Giulio Bondani – IRS

       11:00 Role of research institutions and hospitals in validating innovations

Giovanni Maria Severini – Director Biologist, IRCCS Burlo Garofolo

       11:30 Q&A.

TIChep has obtained funding from the Friuli Venezia Giulia Region on the POR FESR FVG 2014-2020 Call for Proposals: activity 1.3.b – incentives for standard and strategic R&D projects to be carried out through public-private partnerships – SMART HEALTH specialization AREA.

We invite you to participate!

Tichep results published in the journal Cancers

Recreating in vitro conditions similar to those in the body of a patient with ovarian cancer

Check out on this article

https://www.mdpi.com/2072-6694/12/5/1175

Recreating in vitro conditions similar to those in the body of a patient with ovarian cancer is difficult: in culture, cancer cells change morphology and behavior, which makes tests aimed at verifying the effectiveness of chemotherapy drugs unreliable.

To try to overcome this problem, under the POR FESR “Tecnologie Innovative per la Chemioterapia Personalizzata” the company I.R.S., as project leader, IRCCS Burlo Garofolo of Trieste, as project designers and drivers, the CRO of AVIANO, the Department of Life Sciences of the University of Trieste, the Pathology Anatomy of the Department of Medical, Surgical and Health Sciences, and the Oncology Social Center, OSARF, of the Azienda Sanitaria Universitaria Giuliano Isontina, and Alphagenics Biotech, as partners, have initiated a joint study aimed at identifying the best culture conditions for ovarian cancer cells, with an ambitious long-term goal: to establish a personalized treatment protocol for each patient (www. tichep.com).

The first results of the study, published in the journal Cancers [https://www.mdpi.com/2072-6694/12/5/1175], define the importance of using a hyaluronic acid-based extracellular matrix, which makes the culture conditions very similar to those in the patients’ bodies. Working in this way, the researchers confirmed the correspondence between the in vitro reactions of cancer cells toward the chemotherapeutic drug cisplatin, and the in vivo response of patients subjected to the same drug, the first tested in this research.

“Ovarian cancer is also called the ‘silent killer,’ because it generally does not give obvious symptoms except in advanced stages,” explains Giuseppe Ricci, director of the complex structure, obstetrics and gynecology clinic at the Burlo Garofolo in Trieste and University of Trieste. “For several years, here at Burlo Garofolo, we have been investing heavily in interdisciplinary research with various research groups from IRCCS and the University, precisely to develop novel approaches that can increase the success rates of treatments. Every year we have about 25-30 new patients with ovarian cancer who need targeted treatments.”

Tichep project co-financing remakable results!

Check out on this article

https://www.nature.com/articles/s41388-020-01433-6

Oncogene is a peer-reviewed scientific journal published by the Nature Publishing Group addressing cancer cell genetics and the structure and function of oncogenes. The journal aims to make substantial advances in our knowledge of processes that contribute to cancer by publishing outstanding research.

A new important scientific discovery in the research laboratories of the CRO of Aviano: a team made up of molecular Oncology specialists headed by Dr. Gustavo Baldassarre with the statistical advice of Oncological Epidemiology directed by Dr. Diego Serraino has identified a gene responsible for the survival of platinum-based chemotherapy of ovarian cancers.

We are proud to be part of this great result with TiCHEP .

TiCHEP at Meet in Italy for Life Science

Meet TiCHEP Smart Personalized Therapy :
16 octobre, 13.30-14.30 Auditorium at
Meet in Italy for Life Sciences 2019 event, Trieste, Magazzino Molo IV

workshop title: Progetti collaborativi pubblico-privati di Ricerca e Innovazione finanziati dal programma POR-FESR 2014-2020 in FVG

Description (Italian) : verranno presentati alcuni esempi di progetti di Ricerca e Innovazione collaborativi tra le imprese, le Università e gli Enti di Ricerca del Friuli Venezia Giulia in ambito Life Science realizzati grazie ai finanziamenti POR-FESR 2014-2020. La Regione FVG ha investito su 34 progetti con un finanziamento complessivo pari a quasi 17 Mln di euro. Le tematiche progettuali sviluppate, in linea con le traiettorie di sviluppo tecnologico regionali definite dalla S3, vertono sul biomedicale, la diagnostica in vivo e in vitro, l’informatica medica, le terapie personalizzate e le tecnologie dell’Ambient Assisted Living. Al MIT4LS2019 verranno presentati i seguenti cinque progetti di Ricerca e Innovazione:
TICHEP-Tecnologie innovative per una chemioterapia personalizzata
– ARES-Terapia personalizzata di tumore al cervello con tecniche in silico e in vitro;
– BIOSAFE-Rilevamento e analisi di biofilm batterici in ambito ospedaliero, sanitario e domestico.
– DOMINO-Diagnostica ospedaliera molecolare innovativa in NGS per l’oncologia;
– PREDITT-Tecniche innovative per la predizione dei tumori tiroidei;

Scarica il programma.